Introduction {#s1}
============

Community-acquired pneumonia (CAP) is a common and deadly condition. In the United States alone, it is estimated that each year CAP affects 5--6 million people, results in about 1.1 million hospital admissions, and causes the death of over 60,000 Americans, representing the most frequent cause of infectious disease--related mortality and, along with influenza, the overall eighth leading cause of death in this country [@pmed.1001048-Raut1],[@pmed.1001048-File1].

CAP occurs more frequently in the middle aged and the elderly, a population that is also at the highest risk for cardiac diseases [@pmed.1001048-Fry1],[@pmed.1001048-LloydJones1]. Not surprisingly, more than half of elderly patients who present to the hospital with CAP in the United States have preexisting chronic cardiac conditions, and as the population continues to age, this association will become more important [@pmed.1001048-Fry1],[@pmed.1001048-United1].

Acute infections, including CAP, can affect the cardiovascular system in various ways and have been recognized as precipitants of acute cardiac events [@pmed.1001048-Khand1]--[@pmed.1001048-Wattigney1]. Although the possibility of major cardiac complications occurring in a considerable proportion of CAP patients is very plausible, systematic data on the magnitude of this problem are remarkably scant [@pmed.1001048-Fine1]. Given the burden of CAP in North America and other western societies [@pmed.1001048-Raut1],[@pmed.1001048-File1], a careful characterization of the risk of cardiac complications in patients with this infection can have important implications for health policy-making and direct patient care. This systematic review examines the literature published on cardiac complications in patients with CAP in an attempt to characterize the nature and significance of this association, and to identify areas in this field that require further investigation.

Methods {#s2}
=======

The PRISMA checklist is provided in [Text S1](#pmed.1001048.s004){ref-type="supplementary-material"}.

Search Strategy {#s2a}
---------------

Our systematic search strategy was developed to capture all articles of prognosis of CAP in which cardiac complications had been reported and is presented in [Text S2](#pmed.1001048.s005){ref-type="supplementary-material"}. We included articles reporting in English, French, or Spanish languages. We searched the following databases: MEDLINE (from 1950 to June 13, 2010), Scopus (from 1960 to June 13, 2010), and EMBASE (from 1980 to June 13, 2010). Reference lists of selected papers were also screened for additional articles of interest.

Outcomes {#s2b}
--------

Our outcomes consisted of the incidence of cardiac complications as a combined endpoint, incident (new or worsening) heart failure, acute coronary syndromes (ACS; acute myocardial infarction or unstable angina), and incident cardiac arrhythmias within 30 d of CAP diagnosis.

Eligibility Criteria {#s2c}
--------------------

To ensure that the literature reviewed dealt with CAP rather than other conditions, we included only studies in which the definition of CAP was supported by radiographic evidence of acute airspace disease (new or progressing infiltrate within 48 h of presentation), and clinical signs or symptoms of pulmonary infection. Only observational studies reporting the occurrence of any of the cardiac complications of interest in their results or stating the evaluation of these outcomes in their methods were considered. At a minimum, studies had to establish enrolment procedures and inclusion and exclusion criteria in their methodological section, enrol their patients sequentially, and report the incidence of cardiac complications as a function of their entire cohorts.

We excluded studies with focus on nosocomial or health care--associated pneumonia, case series (defined as studies with ≤25 participants), articles without original data, antibiotic efficacy trials (because they are usually restricted to highly selected patients), and articles dealing primarily with pediatric patients or patients infected with the human immunodeficiency virus. We also excluded studies in which the inception time of their cohorts was beyond 48 h from the diagnosis of pneumonia.

Selection of Studies {#s2d}
--------------------

All titles and abstracts of the citations identified by our literature search were independently screened by two investigators (VFC-M and KNS). Relevant articles were reviewed in their entirety. Each investigator made a recommendation for inclusion or exclusion of single articles and if discordant, a third investigator solved the discrepancy (GR). When two or more articles had overlap of their populations and reported on the same cardiac outcomes, only the most inclusive article was considered.

Data Extraction, Synthesis, and Analyses {#s2e}
----------------------------------------

We systematically collected data on the incidence of the cardiac complications of interest, the characteristics of the populations studied, and several aspects of the study setting and methodological design ([Table S1](#pmed.1001048.s002){ref-type="supplementary-material"}). We contacted (by e-mail) the corresponding authors of those papers that offered no details of the methodology followed for the ascertainment of the cardiac complications of interest, and asked them to provide us with copies of the study protocols (or similar) in which this information would be available. Given the aim of our analyses, we focused on how rigorously the evaluation of medical and/or cardiac complications was established in the methodological considerations of these studies as an indicator of their risk of bias in the ascertainment and reporting of these outcomes and their quality relevant to our work. Publication bias was assessed by preparing a funnel plot for the outcome of overall cardiac complications.

Pooled incidence rates of cardiac complications were calculated separately for studies dealing with outpatients, inpatients as a whole, low-risk inpatients (e.g., inpatients with no indication for hospital admission, low-risk pneumonia severity index categories, not requiring admission to intensive care units, etc.), and high-risk inpatients (i.e., patients admitted to intensive care units). We took this approach to prevent heterogeneity in our estimates since these categories represent distinct populations of CAP patients. We performed prespecified subgroup analyses for studies of CAP inpatients by characteristics of their study setting and design, quality indicators of potential bias (see above), and attributes of their populations. Because of the limited number of studies available, these analyses are presented in a descriptive format only. Pooled event rates and their confidence intervals (CIs) were estimated using a random effects model weighted by the inverse variance. When only one study was available, the Agresti-Coull method was used. All analyses were conducted in comprehensive meta-analysis version 2.2.

Results {#s3}
=======

Our search strategy yielded 2,176 articles for review. A flow summary of the selection process is provided in [Figure 1](#pmed-1001048-g001){ref-type="fig"}. [Table 1](#pmed-1001048-t001){ref-type="table"} presents a summarized description of the 25 ultimately selected articles [@pmed.1001048-Allen1]--[@pmed.1001048-CorralesMedina2]. Two studies had overlapping study populations [@pmed.1001048-Musher2],[@pmed.1001048-CorralesMedina2], but since the smaller study reported on each of the four cardiac complications of interest [@pmed.1001048-Musher2], while the larger one reported only data on ACS [@pmed.1001048-CorralesMedina2], we kept both but considered only the latter for analyses related to ACS. One article reported on outpatients and inpatients as separate groups [@pmed.1001048-Fine3], and for purposes of comparative and pooled analyses, each group was treated as a distinct study. [Table S1](#pmed.1001048.s002){ref-type="supplementary-material"} provides the most detailed information on the setting, methodology, population, and findings of the included studies.

![PRISMA flow diagram: selection process.](pmed.1001048.g001){#pmed-1001048-g001}

10.1371/journal.pmed.1001048.t001

###### Studies of cardiac complications in patients with CAP.

![](pmed.1001048.t001){#pmed-1001048-t001-1}

  Reference                                                   Year    *n*                                Population                                          Design              Incidence of Cardiac Complications (%)                
  ---------------------------------------------------------- ------ ------- --------------------------------------------------------------------- ----------------------------- ---------------------------------------- ------ ------ --------------------------------------
  Allen et al. [@pmed.1001048-Allen1]                         1984    502                                Inpatients                                 Prospective single-center                     ---                     ---    \<1                    ---
  Esposito et al. [@pmed.1001048-Esposito1]                   1984    38                 Inpatients[d](#nt104){ref-type="table-fn"}                 Prospective single-center                     ---                     7.9    ---                    ---
  Marrie et al. [@pmed.1001048-Marrie1]                       1989    583                                Inpatients                                 Prospective single-center                     ---                     11.3   ---                    ---
  Ortqvist et al. [@pmed.1001048-Ortqvist1]                   1990    277                                Inpatients                                 Prospective single-center                      13                                  
  Venkatesan et al. [@pmed.1001048-Venkatesan1]               1990    73                                 Inpatients                                 Prospective single-center                     ---                     ---     11                    ---
  Fine et al. [@pmed.1001048-Fine2]                           1990    170    Outpatients and low-risk inpatients[e](#nt105){ref-type="table-fn"}    Prospective single-center                     ---                     ---    0.6                    0.6
  Anonymus [@pmed.1001048-The1]                               1992    60            High-risk inpatients[f](#nt106){ref-type="table-fn"}            Retrospective multicenter                     ---                     ---    23.3                   ---
  Leroy et al. [@pmed.1001048-Leroy1]                         1995    299           High-risk inpatients[f](#nt106){ref-type="table-fn"}           Retrospective single-center                    2.3                     ---    ---                    ---
  Janssens et al. [@pmed.1001048-Janssens1]                   1996    99                                 Inpatients                                 Prospective single-center                     ---                     33.3   ---                    ---
  Fine et al. [@pmed.1001048-Fine3]                           1999    907                                Outpatients                                 Prospective multicenter                      ---                     1.4    0.9                    0.1
  Fine et al. [@pmed.1001048-Fine3]                           1999   1,343                               Inpatients                                  Prospective multicenter                      ---                     20.8   9.5                    3.1
  Musher et al. [@pmed.1001048-Musher1]                       2000    100                Inpatients[d](#nt104){ref-type="table-fn"}                 Prospective single-center                     ---                     ---    ---                     4
  Fernandez Sabé et al. [@pmed.1001048-FernandezSabe1]        2003   1,474                               Inpatients                                 Prospective single-center                     ---                     7.2    ---                    ---
  Fine et al. [@pmed.1001048-Fine4]                           2003    608                                Inpatients                                  Prospective multicenter                       22                     ---    ---                    ---
  Martinez-Moragon et al. [@pmed.1001048-MartinezMoragon1]    2004    91                                 Inpatients                                 Prospective single-center                      5                      ---    ---                    ---
  Menedez et al. [@pmed.1001048-Menendez1]                    2004   1,424           Low-risk inpatients[e](#nt105){ref-type="table-fn"}             Prospective multicenter                      ---                     8.7    ---                    ---
  Querol-Ribelles et al. [@pmed.1001048-QuerolRibelles1]      2005    459            Low-risk inpatients[e](#nt105){ref-type="table-fn"}            Prospective single-center                     ---                     2.6    ---                    ---
  Diaz et al. [@pmed.1001048-Diaz1]                           2005    113           High-risk inpatients[f](#nt106){ref-type="table-fn"}            Prospective single-center                     ---                      24     15                    ---
  Marrie et al. [@pmed.1001048-Marrie2]                       2005    586            Low-risk inpatients[e](#nt105){ref-type="table-fn"}             Prospective multicenter                      ---                     1.4    ---                    0.3
  McAlister et al. [@pmed.1001048-McAlister1]                 2005   2,471           Low-risk inpatients[e](#nt105){ref-type="table-fn"}             Prospective multicenter                      5.9                     ---    ---                    ---
  O\'meara et al. [@pmed.1001048-OMeara1]                     2005    582                                Inpatients                                  Prospective multicenter                       24                     ---    ---                    ---
  Musher et al. [@pmed.1001048-Musher2]                       2007    170                Inpatients[d](#nt104){ref-type="table-fn"}                Retrospective single-center                    19.4                    14.7   5.9     7[g](#nt107){ref-type="table-fn"}
  Becker et al. [@pmed.1001048-Becker1]                       2007    391                                Inpatients                                 Retrospective multicenter                     17.4                    12.3   2.8                    7.9
  Cabré et al. [@pmed.1001048-Cabre1]                         2008    117                                Inpatients                                 Prospective single-center                     ---                      12    4.4                    0.9
  Ramirez et al. [@pmed.1001048-Ramirez1]                     2008    500                                Inpatients                                Retrospective single-center                    ---                     ---    ---                    5.8
  Corrales-Medina et al. [@pmed.1001048-CorralesMedina2]      2009    206                Inpatients[d](#nt104){ref-type="table-fn"}                Retrospective single-center                    ---                     ---    ---    10.7[g](#nt107){ref-type="table-fn"}

Congestive heart failure, atrial fibrillation, severe angina or myocardial infarction or stroke [@pmed.1001048-Ortqvist1]; acute coronary or ventricular insufficiency [@pmed.1001048-Leroy1]; cardiovascular complications likely to necessitate continued hospitalization [@pmed.1001048-Fine4]; cardiac complications without further specification [@pmed.1001048-MartinezMoragon1]; acute coronary syndrome and/or heart failure [@pmed.1001048-McAlister1]; myocardial infarction, angina pectoris, revascularization by angioplasty/coronary artery bypass graft (CABG) or death secondary to coronary heart disease, cerebrovascular accident, congestive heart insufficiency or claudication [@pmed.1001048-OMeara1]; myocardial infarction, atrial fibrillation or ventricular tachycardia or incident heart failure [@pmed.1001048-Musher2]; and myocardial infarction, atrial fibrillation, congestive heart failure or stroke [@pmed.1001048-Becker1].

Incident atrial fibrillation [@pmed.1001048-Allen1],[@pmed.1001048-Venkatesan1],[@pmed.1001048-Fine2],[@pmed.1001048-Becker1],[@pmed.1001048-Cabre1]; cardiac dysrrhythmias/arrhythmias [@pmed.1001048-The1],[@pmed.1001048-Diaz1]; incident atrial arrhythmia [@pmed.1001048-Fine3]; atrial flutter or fibrillation, and ventricular tachycardia, but excluding terminal arrhythmias [@pmed.1001048-Musher2].

Myocardial infarction [@pmed.1001048-Fine2],[@pmed.1001048-Fine3],[@pmed.1001048-Musher1],[@pmed.1001048-Musher2],[@pmed.1001048-Becker1],[@pmed.1001048-Ramirez1]; unstable angina [@pmed.1001048-Marrie2]; acute coronary syndrome [@pmed.1001048-Cabre1],[@pmed.1001048-CorralesMedina2].

Pneumococcal pneumonia [@pmed.1001048-Esposito1],[@pmed.1001048-Musher1],[@pmed.1001048-Musher2]; pneumococcal and *H. influenzae* pneumonia [@pmed.1001048-CorralesMedina2].

Inpatients without severe vital signs or metabolic abnormalities, altered mental status, suppurative complications or coexisting medical conditions requiring hospitalization [@pmed.1001048-Fine2]; inpatients who survived the first 48 h of hospitalization [@pmed.1001048-Menendez1], inpatients not initially admitted to the intensive care unit [@pmed.1001048-QuerolRibelles1],[@pmed.1001048-McAlister1]; inpatients with pneumonia severity index (PSI) risk classes I--II [@pmed.1001048-Marrie2].

Inpatients admitted to the intensive care unit (ICU).

For ACS, patients from Musher et al. (2007) [@pmed.1001048-Musher2] were included in Corrales-Medina et al. (2009) [@pmed.1001048-CorralesMedina2].

Assessment of Quality and Risk of Bias {#s3a}
--------------------------------------

The evaluation of medical and cardiac complications was documented in the methodological considerations of 68% (17 cohorts, *n* = 12,068) and 48% (12 cohorts, *n* = 9,344) of the 25 studies, respectively; whereas definitions of the cardiac complications of interest were available for 24% (six cohorts, *n* = 4,125) of them ([Table S1](#pmed.1001048.s002){ref-type="supplementary-material"}). [Table 2](#pmed-1001048-t002){ref-type="table"} provides the stratification of the articles by these quality elements for each of the cardiac complications of interest. The definitions used for the ascertainment of cardiac complications in the studies for which this information was available is provided in [Table S2](#pmed.1001048.s003){ref-type="supplementary-material"}. Due to the low number of studies, a visual inspection of our funnel plot for overall cardiac complications did not allow for a meaningful assessment of publication bias ([Figure S1](#pmed.1001048.s001){ref-type="supplementary-material"}).

10.1371/journal.pmed.1001048.t002

###### Studies of cardiac complications in patients with CAP: Methodological considerations for the ascertainment of medical and cardiac complications.

![](pmed.1001048.t002){#pmed-1001048-t002-2}

  Outcome                                                                                                               Total *References* (*n*)                                                                                                                         [Methods](#s2){ref-type="sec"} Section Established the Following:                                                                                                                                                          
  ----------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------
  **Overall cardiac complications**                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Outpatients                                                                                                                     ---                                                                                                                                                                   ---                                                                                                                             ---                                                                                                                ---
  Inpatients                                                  *[@pmed.1001048-Ortqvist1],[@pmed.1001048-Fine4],[@pmed.1001048-MartinezMoragon1],[@pmed.1001048-OMeara1]--[@pmed.1001048-Becker1]* (2,119)                           *[@pmed.1001048-Ortqvist1],[@pmed.1001048-Fine4],[@pmed.1001048-MartinezMoragon1],[@pmed.1001048-OMeara1]--[@pmed.1001048-Becker1]* (2,119)                   *[@pmed.1001048-Fine4],[@pmed.1001048-OMeara1]--[@pmed.1001048-Becker1]* (1,751)                                   *[@pmed.1001048-Fine4],[@pmed.1001048-Musher2],[@pmed.1001048-Becker1]* (1,169)
  Low-risk inpatients                                                                                             *[@pmed.1001048-McAlister1]* (2,471)                                                                                                                                 *[@pmed.1001048-McAlister1]* (2,471)                                                                                             *[@pmed.1001048-McAlister1]* (2,471)                                                                                               ---
  High-risk inpatients                                                                                               *[@pmed.1001048-Leroy1]* (299)                                                                                                                                       *[@pmed.1001048-Leroy1]* (299)                                                                                                                ---                                                                                                                ---
  **Incident heart failure**                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  Outpatients                                                                                                        *[@pmed.1001048-Fine3]* (907)                                                                                                                                         *[@pmed.1001048-Fine3]* (907)                                                                                                   *[@pmed.1001048-Fine3]* (907)                                                                                      *[@pmed.1001048-Fine3]* (907)
  Inpatients                           *[@pmed.1001048-Esposito1],[@pmed.1001048-Marrie1],[@pmed.1001048-Janssens1],[@pmed.1001048-Fine3],[@pmed.1001048-FernandezSabe1],[@pmed.1001048-Musher2]--[@pmed.1001048-Cabre1]* (4,215)     *[@pmed.1001048-Marrie1],[@pmed.1001048-Fine3],[@pmed.1001048-FernandezSabe1],[@pmed.1001048-Musher2],[@pmed.1001048-Becker1]* (3,054)                      *[@pmed.1001048-Fine3],[@pmed.1001048-Musher2],[@pmed.1001048-Becker1]* (1,904)                                    *[@pmed.1001048-Fine3],[@pmed.1001048-Musher2],[@pmed.1001048-Becker1]* (1,904)
  Low-risk inpatients                                                                 *[@pmed.1001048-Menendez1],[@pmed.1001048-QuerolRibelles1],[@pmed.1001048-Marrie2]* (2,469)                                                                                       *[@pmed.1001048-Menendez1],[@pmed.1001048-QuerolRibelles1]* (1,883)                                                             *[@pmed.1001048-Menendez1],[@pmed.1001048-QuerolRibelles1]* (1,883)                                                                                ---
  High-risk inpatients                                                                                               *[@pmed.1001048-Diaz1]* (113)                                                                                                                                         *[@pmed.1001048-Diaz1] (113)*                                                                                                   *[@pmed.1001048-Diaz1]* (113)                                                                                                   ---
  **ACS**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  Outpatients                                                                                                        *[@pmed.1001048-Fine3]* (907)                                                                                                                                         *[@pmed.1001048-Fine3]* (907)                                                                                                   *[@pmed.1001048-Fine3] (907)*                                                                                      *[@pmed.1001048-Fine3]* (907)
  Inpatients                                                      *[@pmed.1001048-Fine3],[@pmed.1001048-Musher1],[@pmed.1001048-Becker1]--[@pmed.1001048-Ramirez1],[@pmed.1001048-Menendez1]* (2,657)                                            *[@pmed.1001048-Fine3],[@pmed.1001048-Becker1],[@pmed.1001048-Ramirez1],[@pmed.1001048-CorralesMedina2]* (2,440)                 *[@pmed.1001048-Fine3],[@pmed.1001048-Becker1],[@pmed.1001048-Ramirez1],[@pmed.1001048-CorralesMedina2]* (2,440)   *[@pmed.1001048-Fine3],[@pmed.1001048-Becker1],[@pmed.1001048-Ramirez1],[@pmed.1001048-CorralesMedina2]* (2,440)
  Low-risk inpatients                                                                                               *[@pmed.1001048-Marrie2]* (586)                                                                                                                                                     ---                                                                                                                             ---                                                                                                                ---
  High-risk inpatients                                                                                                            ---                                                                                                                                                                   ---                                                                                                                             ---                                                                                                                ---
  **Incident cardiac arrhythmias**                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  Outpatients                                                                                                        *[@pmed.1001048-Fine3]* (907)                                                                                                                                         *[@pmed.1001048-Fine3]* (907)                                                                                                   *[@pmed.1001048-Fine3]* (907)                                                                                      *[@pmed.1001048-Fine3]* (907)
  Inpatients                                                       *[@pmed.1001048-Allen1],[@pmed.1001048-Venkatesan1],[@pmed.1001048-Fine3],[@pmed.1001048-Musher2]--[@pmed.1001048-Cabre1]* (2,596)                                                             *[@pmed.1001048-Fine3],[@pmed.1001048-Musher2],[@pmed.1001048-Becker1] (1,904)*                                                 *[@pmed.1001048-Fine3],[@pmed.1001048-Musher2],[@pmed.1001048-Becker1]* (1,904)                                    *[@pmed.1001048-Fine3],[@pmed.1001048-Musher2],[@pmed.1001048-Becker1]* (1,904)
  Low-risk inpatients                                                                                                             ---                                                                                                                                                                   ---                                                                                                                             ---                                                                                                                ---
  High-risk inpatients                                                                                     *[@pmed.1001048-The1],[@pmed.1001048-Diaz1]* (173)                                                                                                                              *[@pmed.1001048-Diaz1] (113)*                                                                                                   *[@pmed.1001048-Diaz1]* (113)                                                                                                   ---

One study reporting the incidence of ACS and incident cardiac arrhythmias on outpatients and low-risk inpatients without making distinction between them was not included in this table [@pmed.1001048-Fine2].

Overall Cardiac Complications {#s3b}
-----------------------------

Six studies focused on CAP inpatients [@pmed.1001048-Ortqvist1],[@pmed.1001048-Fine4],[@pmed.1001048-MartinezMoragon1],[@pmed.1001048-OMeara1]--[@pmed.1001048-Becker1], one on low-risk inpatients [@pmed.1001048-McAlister1], and one on high-risk inpatients [@pmed.1001048-Leroy1]; with pooled incidence rates of 17.7% (CI 13.9--22.2) 5.9% (5.0--6.9), and 2.3% (1.0--4.9) for each of these groups, respectively ([Figure 2](#pmed-1001048-g002){ref-type="fig"}).

![Pooled rates of the incidence of cardiac complications in patients with CAP.\
One study reporting the incidence of ACS and incident cardiac arrhythmias on outpatients and low-risk inpatients without making distinction between them was not included in the calculations of pooled rates [@pmed.1001048-Fine2]. ^a^For definitions refer to [Table 1](#pmed-1001048-t001){ref-type="table"}. ^b^Low-risk inpatients included studies of inpatients with no indication for hospital admission, pneumonia severity index (PSI) risk-classes I--II, not initially admitted to intensive care units or who survived the first 48 h of hospitalization. High-risk inpatients included patients admitted to intensive care units. ^c^When only one study was available, the reported rate represents the study event rate.](pmed.1001048.g002){#pmed-1001048-g002}

Incident Heart Failure {#s3c}
----------------------

One study reported on outpatients [@pmed.1001048-Fine3], eight on inpatients [@pmed.1001048-Esposito1],[@pmed.1001048-Marrie1],[@pmed.1001048-Janssens1],[@pmed.1001048-Fine3],[@pmed.1001048-FernandezSabe1],[@pmed.1001048-Musher2]--[@pmed.1001048-Cabre1], three on low-risk inpatients [@pmed.1001048-Menendez1],[@pmed.1001048-QuerolRibelles1],[@pmed.1001048-Marrie2] and one on high-risk inpatients [@pmed.1001048-Diaz1]. The pooled incidence rates for each of these groups were 1.4% (0.8--2.5), 14.1% (9.3--20.6), 3.3% (1.0--10.5), and 23.9% (16.9--32.6), respectively ([Figure 2](#pmed-1001048-g002){ref-type="fig"}).

Acute Coronary Syndromes {#s3d}
------------------------

Five studies reported only on myocardial infarction [@pmed.1001048-Fine2],[@pmed.1001048-Fine3],[@pmed.1001048-Musher1],[@pmed.1001048-Becker1],[@pmed.1001048-Ramirez1], one on unstable angina [@pmed.1001048-Marrie2], and two on ACS in general [@pmed.1001048-Cabre1],[@pmed.1001048-CorralesMedina2]. One study reported on outpatients and low-risk inpatients without making distinction between them and was not accounted for in the calculations of pooled rates [@pmed.1001048-Fine2]. One study focused on outpatients [@pmed.1001048-Fine3], six on inpatients [@pmed.1001048-Fine3],[@pmed.1001048-Musher1],[@pmed.1001048-Becker1]--[@pmed.1001048-CorralesMedina2], and one on low-risk inpatients [@pmed.1001048-Marrie2], with pooled incidence rates of 0.1% (0.0--0.7), 5.3% (3.2--8.6), and 0.3% (0.01--1.3), respectively ([Figure 2](#pmed-1001048-g002){ref-type="fig"}).

Incident Cardiac Arrhythmias {#s3e}
----------------------------

Five studies reported solely on atrial fibrillation [@pmed.1001048-Allen1],[@pmed.1001048-Venkatesan1],[@pmed.1001048-Fine2],[@pmed.1001048-Becker1],[@pmed.1001048-Cabre1], one study on all atrial arrhythmias [@pmed.1001048-Fine3], two on cardiac arrhythmias in general [@pmed.1001048-The1],[@pmed.1001048-Diaz1], and one on atrial fibrillation (88% of the cases) and ventricular arrhythmias (excluding terminal arrhythmias) [@pmed.1001048-Musher2]. One study reporting on outpatients and low-risk inpatients without making distinction between them was not included in the calculations of pooled rates [@pmed.1001048-Fine2]. One study evaluated outpatients [@pmed.1001048-Fine3], six studied inpatients [@pmed.1001048-Allen1],[@pmed.1001048-Venkatesan1],[@pmed.1001048-Fine3],[@pmed.1001048-Musher2]--[@pmed.1001048-Cabre1], and two focused on high-risk inpatients [@pmed.1001048-The1],[@pmed.1001048-Diaz1]; giving pooled incidence rates of 0.9% (0.4--1.8), 4.7% (2.4--8.9), and 18.5% (11.8--27.8), respectively ([Figure 2](#pmed-1001048-g002){ref-type="fig"}).

Subgroup Analyses {#s3f}
-----------------

[Tables 3](#pmed-1001048-t003){ref-type="table"} and [4](#pmed-1001048-t004){ref-type="table"} describe the results of prespecified subgroup analyses of studies on CAP inpatients by characteristics of their setting, methodology, and population. Incident cardiac arrhythmias and incident heart failure were more common in papers published before 2000 and those coming from Europe. Overall cardiac complications and ACS, on the other hand, were more frequent in studies published between 2000 and 2005, and after 2005, respectively, and in papers coming from North America. All cardiac complications but ACS were more common in studies of prospective multicenter design. Additionally, all cardiac complications tended to occur more frequently in studies in which the evaluation of these events was stated in their methodological considerations or a definition for their ascertainment was available.

10.1371/journal.pmed.1001048.t003

###### Studies of cardiac complications in inpatients with CAP: Subgroup analysis by study setting and design.

![](pmed.1001048.t003){#pmed-1001048-t003-3}

  Subgroups                                                                                                       Overall Cardiac Complications   Incident Heart Failure   ACS   Incident Cardiac Arrhythmias                                
  -------------------------------------------------------------------------------------------------------------- ------------------------------- ------------------------ ----- ------------------------------ ----- ----------------- ----- -----------------
  [Year:]{.ul}                                                                                                                                                                                                                               
  Before 2000                                                                                                                   1                    13.0 (9.5--17.5)       4         18.1 (10.8--28.7)          1    3.1 (2.3--4.2)     3    5.1 (1.5--15.7)
  2000--2005                                                                                                                    3                   19.0 (13.3--26.3)       1           7.2 (6.0--8.6)           1    4.0 (1.2--10.2)   ---         ---
  2006+                                                                                                                         2                   18.0 (15.1--21.4)       3         12.9 (10.5--15.6)          4    7.1 (4.5--10.8)    3    4.1 (2.5--6.5)
  [Region:]{.ul}                                                                                                                                                                                                                             
  North America                                                                                                                 4                   21.0 (18.2--24.2)       5          13.9 (9.7--19.5)          5    5.9 (3.6--9.5)     3    5.6 (2.6--11.8)
  Latin America                                                                                                                ---                         ---             ---               ---                ---         ---         ---         ---
  Europe                                                                                                                        2                    9.3 (4.0--20.2)        3          15.1 (4.7--39.0)          1    0.9 (0.0--5.2)     2    7.1 (2.8--17.10
  Asia                                                                                                                         ---                         ---             ---               ---                ---         ---         ---         ---
  Africa                                                                                                                       ---                         ---             ---               ---                ---         ---          1    1.0 (0.4--2.4)
  Oceania                                                                                                                      ---                         ---             ---               ---                ---         ---         ---         ---
  [Design:]{.ul}                                                                                                                                                                                                                             
  Prospective single---center                                                                                                   2                    9.3 (4.0--20.2)        5          13.0 (6.9--23.0)          2    2.3 (0.5--9.5)     3    3.7 (0.9--14.2)
  Prospective multicenter                                                                                                       2                   23.0 (20.7--25.5)       1         20.8 (18.7--23.0)          1    3.1 (2.3--4.2)     1    9.5 (8.1--11.2)
  Retrospective                                                                                                                 2                   18.0 (15.1--21.4)       2         13.1 (10.5--16.1)          3    7.8 (5.6--10.8)    2    4.0 (1.9--8,2)
  [Evaluation of medical complications stated in]{.ul} [[Methods]{.ul}](#s2){ref-type="sec"} [section:]{.ul}                                                                                                                                 
  No                                                                                                                           ---                         ---              3          16.7 (5.9--39.0)          2    2.3 (0.5--9.5)     3    3.7 (0.9--14.2)
  Yes                                                                                                                           6                   17.7 (13.9--22.2)       5          12.6 (7.8--19.8)          4    6.2 (3.6--10.5)    3    5.6 (2.6--11.8)
  [Evaluation of cardiac complications stated in]{.ul} [[Methods]{.ul}](#s2){ref-type="sec"} [section:]{.ul}                                                                                                                                 
  No                                                                                                                            2                    9.3 (4.0--20.2)        5          13.0 (6.9--23.0)          2    2.3 (0.5--9.5)     3    3.7 (0.9--14.2)
  Yes                                                                                                                           4                   21.0 (18.2--24.2)       3         15.9 (10.8--22.8)          4    6.2 (3.6--10.5)    3    5.6 (2.6--11.8)
  [Definition of cardiac complications provided in]{.ul} [[Methods]{.ul}](#s2){ref-type="sec"} [section:]{.ul}                                                                                                                               
  No                                                                                                                            3                    13.5 (6.7--25.3)       5          13.0 (6.9--23.0)          2    2.3 (0.5--9.5)     3    3.7 (0.9--14.2)
  Yes                                                                                                                           2                   20.0 (17.0--23.2)       3         15.9 (10.8--22.8)          4    6.2 (3.6--10.5)    3    5.6 (2.6--11.8)

One study reporting the incidence of ACS and incident cardiac arrhythmias on outpatients and low-risk inpatients without making distinction between them was not included in this table [@pmed.1001048-Fine2].

10.1371/journal.pmed.1001048.t004

###### Studies of cardiac complications in inpatients with CAP: subgroup analysis by baseline characteristics of the population.

![](pmed.1001048.t004){#pmed-1001048-t004-4}

  Subgroups                                             Overall Cardiac Complications   Incident Heart Failure   ACS   Incident Cardiac Arrhythmias                                
  ---------------------------------------------------- ------------------------------- ------------------------ ----- ------------------------------ ----- ----------------- ----- ------------------
  [Age]{.ul}                                                                                                                                                                       
  \<50                                                               ---                         ---             ---               ---                ---         ---          1     1.0 (0.4--2.4)
  50--65                                                             ---                         ---              3          13.9 (7.8--23.5)          2    3.2 (2.4--4.2)     1    9.5 (8.1--11.2)
  \>65                                                                5                   17.2 (13.0--22.4)       4          14.3 (6.9--27.4)          4    7.1 (4.5--10.8)    3    5.1 (2.1--11.7)
  Not reported                                                        1                   19.4 (14.1--26.0)       1         14.7 (10.1--20.9)         ---         ---          1    5.9 (3.1--10.6)
  [Gender:]{.ul}                                                                                                                                                                   
  \<50% Male                                                          4                   16.7 (11.6--23.5)       2          19.1 (3.7--59.0)         ---         ---         ---         ---
  \>50%+ Male                                                         2                   18.0 (15.1--21.4)       6          12.5 (8.1--18.8)          6    5.3 (3.2--8.6)     6     4.7 (2.4--8.9)
  [Preexisting cardiac/cardiovascular disease:]{.ul}                                                                                                                               
  \<25%                                                              ---                         ---             ---               ---                ---         ---         ---         ---
  25--50%                                                            ---                         ---             ---               ---                ---         ---         ---         ---
  50%+                                                               ---                         ---             ---               ---                ---         ---         ---         ---
  Not reported                                                        6                   17.7 (13.9--22.2)       8          14.1 (9.3--20.6)          6    5.3 (3.2--8.6)     6     4.7 (2.4--8.9)
  [Coronary artery disease:]{.ul}                                                                                                                                                  
  \<25%                                                              ---                         ---              1          12.0 (7.1--19.2)          1    0.9 (0.0--5.2)     1     4.3 (1.6--9.9)
  25--50%                                                             2                   23.0 (20.7--25.5)       3          13.9 (7.8--23.5)          3    5.8 (2.8--11.3)    1    9.5 (8.1--11.2)
  50%+                                                               ---                         ---             ---               ---                ---         ---         ---         ---
  Not reported                                                        4                   14.5 (10.4--19.8)       4          15.0 (7.5--27.9)          2    6.5 (3.5--11.7)    4     3.8 (1.5--9.2)
  [Congestive heart failure:]{.ul}                                                                                                                                                 
  \<25%                                                               4                   18.8 (14.3--24.3)       2          16.3 (9.5--26.5)          3    6.4 (3.0--13.3)    2    5.4 (1.6--16.8)
  25--50%                                                            ---                         ---              1          12.0 (7.1--19.2)          3    4.1 (1.9--8.5)     1     4.3 (1.6--9.9)
  50%+                                                               ---                         ---             ---               ---                ---         ---         ---         ---
  Not reported                                                        2                   15.9 (10.6--23.1)       5          13.5 (7.4--23.5)         ---         ---          3    4.2 (1.1--14.1)
  [Diabetes mellitus:]{.ul}                                                                                                                                                        
  \<25%                                                               3                   21.3 (17.9--25.1)       5          11.6 (6.8--19.0)          3    6.4 (3.0--13.3)    2    5.4 (1.6--16.8)
  25--50%                                                             1                    5.5 (2.1--12.5)        1          12.0 (7.1--19.2)          2    2.9 (0.5--16.0)    1     4.3 (1.6--9.9)
  50%+                                                               ---                         ---             ---               ---                ---         ---         ---         ---
  Not reported                                                        2                   15.6 (10.6--23.1)       2          23.5 (9.0--48.8)          1    4.0 (1.2--10.2)    3    4.2 (1.1--14.1)
  [Chronic obstructive pulmonary disease:]{.ul}                                                                                                                                    
  \<25%                                                               4                   15.2 (10.0--22.4)       3          9.1 (5.8--14.2)           1    7.9 (5.6--11.1)    1     2.8 (1.5--5.0)
  25--50%                                                             1                   22.0 (18.9--25.5)       2          15.6 (8.4--27.2)          3    5.8 (2.8--11.3)    1    9.5 (8.1--11.2)
  50%+                                                               ---                         ---              1          12.0 (7.1--19.2)          2    2.3 (0.5--9.5)     1     4.3 (1.6--9.9)
  Not reported                                                        1                   19.4 (14.1--26,0)       2          23.5 (9.0--48.8)         ---         ---          3    4.2 (1.1--14.1)
  [Smoking:]{.ul}                                                                                                                                                                  
  \<25%                                                               1                   24.1 (20.8--27.7)      ---               ---                ---         ---         ---         ---
  25--50%                                                            ---                         ---              2          11.1 (8.9--13.9)          1    5.8 (4.0--8.2)     1    11.0 (5.4--20.4)
  50%+                                                               ---                         ---             ---               ---                 2    7.2 (2.7--17.7)   ---         ---
  Not reported                                                        5                   16.2 (12.2--21.1)       6          15.4 (9.3--24.3)          3    3.9 (1.6--9.2)     5     3.9 (1.8--8.4)

One study reporting the incidence of ACS and incident cardiac arrhythmias on outpatients and low-risk inpatients without making distinction between them was not included in this table [@pmed.1001048-Fine2].

Incident heart failure, incident cardiac arrhythmias, and ACS tended to be more common in studies with older populations and higher rates of preexisting coronary artery disease, but not in those with higher prevalence of preexisting congestive heart failure. Studies of predominantly female populations had higher incidences of incident heart failure, whereas the opposite was observed for overall cardiac complications. Rates of all cardiac complications but incident heart failure were lower in studies of patients with higher prevalence of diabetes mellitus. While overall cardiac complications, incident heart failure and incident cardiac arrhythmias were more common in studies with higher prevalence of chronic obstructive pulmonary disease, the opposite was observed for ACS. Finally, ACS occurred more commonly in studies of patients with higher rates of smoking.

Risk Factors and Impact of Cardiac Complications on CAP Outcomes {#s3g}
----------------------------------------------------------------

Only three studies [@pmed.1001048-Becker1],[@pmed.1001048-Ramirez1],[@pmed.1001048-CorralesMedina2], all dealing with CAP and ACS, attempted to analyze risk factors for the occurrence of cardiac complications. Possible risk factors identified included older age, preexisting congestive heart failure [@pmed.1001048-CorralesMedina2], severity of pneumonia [@pmed.1001048-Ramirez1], and the use of insulin by glucose sliding scales in hospitalized patients [@pmed.1001048-Becker1]. No study analyzed the association of cardiac complications with the development of other medical complications (i.e., acute renal failure, respiratory failure, shock, etc.), or the impact of these events on other CAP outcomes (i.e., mortality).

Discussion {#s4}
==========

Our main finding is that major cardiac complications occur in a significant proportion of patients with CAP, especially in those requiring hospitalization for this infection. The pooled incidence rates of overall cardiac complications, incident heart failure, ACS, and incident arrhythmias in hospitalized patients with CAP were 17.7%, 14.1%, 5.3%, and 4.7%, respectively. Given the burden of CAP in North America and other western societies [@pmed.1001048-Raut1],[@pmed.1001048-File1], these pooled findings have important implications. Firstly, clinicians need to realize the significance of this association for appropriate clinical alertness and to better inform CAP patients about the risk of cardiac complications once the diagnosis of pneumonia is made. Secondly, physicians and health officials need to increase efforts to optimize the rates of influenza and pneumococcal vaccination among the elderly and those with chronic cardiac conditions to reduce the incidence of CAP in these high-risk populations. Thirdly, attention needs to be directed to the potential impact of cardiac complications in the mortality and cost associated with CAP. Finally, the research community needs to urgently direct more efforts to the study of this area.

Our results expand on the findings of Fine et al. [@pmed.1001048-Fine1], who in the only previous systematic review on this topic reported four CAP cohorts (232 patients total) with a pooled incidence of heart failure of 8.6%. Our study not only confirms that incident heart failure is common in the course of CAP but suggests that its occurrence in patients hospitalized with this infection may be much higher than previously realized, and that ACS and cardiac arrhythmias are also remarkably frequent in this population.

Incident heart failure can be precipitated by CAP by several mechanisms [@pmed.1001048-CorralesMedina1],[@pmed.1001048-Musher2]. Acute inflammation can not only depress myocardial function, as it is well described in septic states [@pmed.1001048-Maeder1],[@pmed.1001048-Suffredini1], but it can also increase large artery stiffness and the pulse wave reflections from peripheral middle-sized and small arteries that return to the heart in late systole, increasing left ventricular afterload and raising oxygen consumption [@pmed.1001048-Chirinos1]. Hypoxemia associated with CAP can raise pulmonary arterial pressure and right ventricular afterload while impairing myocardial oxygen delivery [@pmed.1001048-CorralesMedina1]. Tachycardia, common in acute infections, increases myocardial oxygen needs but shortens the diastolic period in which coronary perfusion occurs [@pmed.1001048-Ferro1]--[@pmed.1001048-Merkus1]. The net result of these effects is a shift in the metabolic supply/demand ratio of the myocardium and further impairment of its function. These changes are presumed to be of greater significance in patients with preexisting cardiac disease. In addition, incident heart failure in CAP can result from myocardial inflammation (myocarditis), a complication well described in patients with pneumonia mainly of viral origin, and that could have been underrepresented in previous investigations because of a lack of adequate noninvasive techniques for its identification (i.e., cardiac magnetic resonance imaging) [@pmed.1001048-Mavrogeni1]. Finally, we realize that acute renal impairment, common in hospitalized CAP patients [@pmed.1001048-Fine3], can also play a role in this setting [@pmed.1001048-Bock1].

Acute infections, including CAP, can also trigger the occurrence of ACS, and clinical studies have shown a significant temporal increase in the risk of ACS soon after the development of respiratory infections [@pmed.1001048-CorralesMedina2],[@pmed.1001048-Clayton1],[@pmed.1001048-Smeeth1]. Surges of biomechanical stress, as a result of increased sympathetic activity and other hemodynamic changes (i.e. alterations of the circulatory volume and the systemic and coronary vascular tone), can prompt plaque rupture [@pmed.1001048-CorralesMedina1]. Acute infections can also promote plaque disruption by increasing intraplaque inflammatory activity [@pmed.1001048-CorralesMedina1]. In this setting, thrombus formation over a disrupted coronary plaque---a key step in the development of ACS---would be favoured by infection-induced prothrombotic changes in the blood and endothelium [@pmed.1001048-CorralesMedina1]. In addition, preexisting coronary artery disease that doesn\'t produce myocardial ischemia under baseline conditions can result in significant ischemia in the face of increased metabolic demands associated with CAP (i.e., demand ischemia; see above).

Most of the cardiac arrhythmias reported in the reviewed studies represented atrial tachyarrhythmias, particularly atrial fibrillation. Abnormalities in the cardiac conduction system in the setting of acute pneumonia have been recognized since the early 20th century and consistently confirmed thereafter [@pmed.1001048-Degraff1],[@pmed.1001048-Morganroth1]. More recently, a study of more than 800,000 patients admitted to the hospital with atrial fibrillation as a secondary condition found that in patients 65 y of age or older, the second leading primary diagnosis was pneumonia (7%), after only congestive heart failure (13%), and before acute myocardial infarction (6%) [@pmed.1001048-Wattigney1].

While incident heart failure, ACS, and cardiac arrhythmias constitute distinct clinical entities, they share many pathophysiological bases and risk factors, and the occurrence of one of them can as well trigger the development of the others. While only one study in our review clearly documented the frequent concomitant occurrence of more than one cardiac complication in CAP patients [@pmed.1001048-Musher2], we think that this scenario is likely to be rather common.

Our study highlights several shortcomings of the medical literature on this area, which might influence our interpretations. Only a small proportion of studies primarily focused on cardiac outcomes and very few provided a definition for them, raising concerns for potential bias in the ascertainment and/or reporting of these events in those studies that did not. This is relevant especially for incident heart failure and ACS since their manifestations can overlap with those of CAP and other associated conditions (i.e., lung injury). Nevertheless, the few studies that provided clear definitions for the cardiac complications of interest consistently reported substantial incidences of these outcomes, providing reassurance for the validity of our findings. Only three studies of CAP and ACS looked at possible risk factors for the occurrence of these events but their analyses were largely underpowered and limited [@pmed.1001048-Becker1],[@pmed.1001048-Ramirez1],[@pmed.1001048-CorralesMedina2]. While it seems intuitive to think that the presence of preexisting cardiac conditions should have an important effect on the risk of cardiac complications in patients with CAP, further research will be needed to delineate their significance in this setting. As well, the association of cardiac complications with the development of other medical complications (i.e., acute renal failure, respiratory failure, shock, etc.), or the impact of these events in other CAP outcomes (i.e., mortality) is yet to be established. Finally, little is known about the timing of these complications, and only one study suggested that ACS in CAP patients tend to occur within few days after hospital admission [@pmed.1001048-CorralesMedina2].

Our work has limitations beyond the methodological shortcomings of the individual analyzed studies. We cannot rule out potential publication bias against studies that found no significant occurrences of cardiac complications. Additionally, we can only assume that the diagnostic evaluations in individual studies were performed in a uniform manner and the ascertainment of cardiac events was correct. The small number of studies dealing with CAP populations other than inpatients as a whole prevents us from drawing firm conclusions on the incidence of cardiac complications in these groups; and the finding of a counter-intuitively lower incidence of overall cardiac complications in high-risk CAP inpatients could be explained by this factor. The implied differences in the management of inpatients and outpatients may have led to the under-reporting of cardiac events in studies dealing with the latter group. Although studies of cardiac complications in CAP inpatients were the most common in our review, their number was still underpowered for performing adequate analyses (i.e., meta-regression) of factors that could account for the heterogeneity in their findings, and any appreciable difference observed in our subgroup analyses should be viewed in this context. Our review was limited to cardiac complications occurring within 30 d from presentation with CAP because it is assumed that the influence of the infection on patients\' comorbid conditions is maximal during this time [@pmed.1001048-Musher3]; however, it is plausible that this influence can go beyond this period as it has been suggested by recent studies [@pmed.1001048-Smeeth1],[@pmed.1001048-Yende1]. Likewise, many of the mechanisms implicated in the development of cardiac complications in patients with CAP could account for similar occurrences in other infectious and noninfectious acute inflammatory states [@pmed.1001048-CorralesMedina1]. In fact, evidence suggests that acute infections of the urinary and gastrointestinal tract are also associated with increased risk of ACS in the short term [@pmed.1001048-CorralesMedina1],[@pmed.1001048-Smeeth1],[@pmed.1001048-Baylin1]. However, exploring the magnitude of these associations was beyond the scope of our review.

Our findings highlight the urgent need for prospective, well-designed, and adequately powered studies of cardiac complications in patients with CAP. Investigations should focus on identifying risk factors for the occurrence of cardiac complications in this population and developing strategies to identify those CAP patients at high risk for developing these events. These strategies may include clinical scoring systems, biomarker-based approaches, noninvasive cardiac imaging, or a combination of these. Studies are also needed to characterize the impact of cardiac complications on the mortality and resource utilization associated with CAP. Careful mechanistic studies of the pathophysiology of cardiac complications in the course of CAP and the role of preexisting heart disease in their development should serve for the appropriate design of interventions aimed at preventing their occurrence in high-risk groups. As an example, discriminating between acute plaque rupture versus demand ischemia as the factor driving the occurrence of ACS in this population will have important and obvious therapeutic implications. Such interventions will need to be tested in randomized clinical trials. The ultimate goal will be to improve the outcomes of patients with CAP and to decrease the burden that this disease imposes on our health care systems through recognition of risk, prevention, and intervention on acute cardiac complications.
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